Sign inJoin waitlistJoin the waitlist

MV

Miguel Villalona-Calero

Division Chief · University of California

Credentials: · · · · · · ·

History

University of California
Present
Medicine Division · University of California
Present
and deputy director of the Chao Family Comprehensive Cancer Center. Division · University of California
Present

Medical Oncology
1988–1990
Internal Medicine
1985–1988
Doctor of Medicine
1981–1985

Research

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer
Clinical Cancer Research · 2019 · 483 citations
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
Proceedings of the National Academy of Sciences of the United States of America · 2010 · 393 citations
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity
Review · Annals of Oncology · 2002 · 331 citations

GO
Gregory Otterson
49 papers
DH
Daniel Von Hoff
19 papers
Tanios Bekaii-Saab
16 papers
MG
Michael Grever
15 papers
Gail Eckhardt
14 papers
RD
Ronald Drengler
13 papers
ER
Eric Rowinsky
12 papers
Weiqiang Zhao
10 papers
CS
Charles Shapiro
8 papers
Konstantin Shilo
8 papers
RS
Ravi Salgia
8 papers
GW
Geoffrey Weiss
7 papers

Grants

Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
National Cancer Institute · R01
Contact PI · $1.8M · University of California-Irvine
2022–2028
Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN
National Cancer Institute · UM1
Contact PI · $7.5M · Beckman Research Institute/City of Hope
2014–2026
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $61.8K · Beckman Research Institute/City of Hope
1997–2023
Training Hematology and Oncology Fellows in Clinical Research
National Cancer Institute · T32
Contact PI · $534.1K · Ohio State University
2012–2017

Clinical trials

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
Principal investigator · Active not recruiting · Phase 1
University of California, Irvine
2022–2027
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Principal investigator · Completed · Phase 2
Oncolytics Biotech
2009–2015
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Principal investigator · Terminated · Phase 2
Ohio State University Comprehensive Cancer Center
2008–2012
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 2
Ohio State University Comprehensive Cancer Center
2005–2013